Clinical Trial Update: Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma [NA]

View source ↗

Summary

This clinical trial update describes the development and prospective validation of a heterogeneous treatment effect-based decision model for transarterial chemo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Avastin (bevacizumab) (bevacizumab)
• Tecentriq (atezolizumab) (atezolizumab)

Snippet

Sponsor: Zhongda Hospital | Conditions: HCC - Hepatocellular Carcinoma | NA | Status: NOT_YET_RECRUITING